Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 31, 2002

Primary Completion Date

August 31, 2004

Study Completion Date

August 31, 2004

Conditions
HIV Infection
Interventions
DRUG

abacavir/lamivudine/zidovudine

DRUG

tenofovir

Trial Locations (27)

10014

GSK Investigational Site, New York

10461

GSK Investigational Site, The Bronx

10595

GSK Investigational Site, Valhalla

30033

GSK Investigational Site, Decatur

30309

GSK Investigational Site, Atlanta

32206

GSK Investigational Site, Jacksonville

32303

GSK Investigational Site, Tallahassee

32804

GSK Investigational Site, Orlando

33136

GSK Investigational Site, Miami

33139

GSK Investigational Site, Miami Beach

33145

GSK Investigational Site, Fort Lauderdale

33161

GSK Investigational Site, North Miami

33463

GSK Investigational Site, Lake Worth

47904

GSK Investigational Site, Lafayette

48072

GSK Investigational Site, Berkeley

54301

GSK Investigational Site, Green Bay

60153

GSK Investigational Site, Maywood

60657

GSK Investigational Site, Chicago

74114

GSK Investigational Site, Tulsa

75208

GSK Investigational Site, Dallas

75216

GSK Investigational Site, Dallas

75246

GSK Investigational Site, Dallas

76015

GSK Investigational Site, Arlington

77004

GSK Investigational Site, Houston

90027

GSK Investigational Site, Los Angeles

94903

GSK Investigational Site, San Rafael

98104

GSK Investigational Site, Seattle

Sponsors

Lead Sponsor

All Listed Sponsors
lead

ViiV Healthcare

INDUSTRY